AMRI, a US-headquartered global contract research and manufacturing organisation, has appointed Ian Shott as president of AMRI Europe.
In this newly created role, Shott will have responsibility for AMRI’s business operations in Europe, including the company’s site in Wales.
Shott has more than 20 years’ experience working with global pharmaceutical, biotechnology, and chemical companies. In his new role he will lead AMRI’s sales growth in European markets.
Shott was the founder and ceo of Excelysn, now AMRI UK, which was acquired in 2010. He serves as managing director of Shott Consulting, where he provides consultancy services to the healthcare and chemical industries, as well as industry boards in Science, Technology, Innovation and Business Development for the UK Government.
‘Ian Shott brings an intimate knowledge of the AMRI UK site including its capabilities and leadership team, which will enable him quickly to embark on customer and business growth initiatives,’ said Thomas D’Ambra, chairman, president and ceo of AMRI.
‘His extensive experience and skills strengthen our position in the European marketplace.’
Shott’s earlier career included board posts at RhodiaChirex in France, Chirex in the US, Lonza in Switzerland, and Astra Zeneca in the UK.